Oxford BioDynamics launching oncology test in the U.K.

By LabPulse.com staff writers

June 21, 2022 -- Oxford BioDynamics on Tuesday announced that its Checkpoint inhibitor Response Test (CiRT) is now available to private physicians considering immune checkpoint inhibitor (ICI) therapy for patients in the U.K.

The company noted that its EpiSwitch CiRT blood test predicts the likelihood of a cancer patient's response to ICI therapeutics that include anti-PD-L1 and anti-PD-1 immunotherapies.

The qPCR test has demonstrated a 93% sensitivity, 82% specificity, 85% accuracy, and 93% negative predictive value (NPV) across ICIs from numerous pharmaceutical companies as well as more than 15 key oncological indications, including melanoma and lung cancer, Oxford BioDynamics noted.

InterVenn Biosciences announces clinical data for melanoma test
InterVenn Biosciences has announced clinical validation data for its Dawn IO Melanoma liquid biopsy test.
Oxford BioDynamics launches EpiSwitch oncology test
Oxford BioDynamics announced the clinical validation and U.S. launch of its EpiSwitch checkpoint inhibitor response test (CiRT) for oncology.
TMB test predicts immunotherapy effects in lung cancer patients
The level of tumor mutational burden (TMB) in blood appears to be an effective biomarker for gauging response to immunotherapies and survival in patients...
Agilent's PD-L1 test gets OK for head, neck cancer in Europe
Agilent Technologies' programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay has been labeled for use in patients with head...
Merck KGaA, Personalis team up on cancer biomarkers
Merck KGaA will use the ImmunoID NeXT immunogenomics platform of Personalis to develop biomarkers for cancer therapies through a new collaboration.

Copyright © 2022 LabPulse.com

Last Updated mp 6/21/2022 10:26:00 AM